Preferred Label : Immunotherapeutic Combination Product CMB305;
NCIt synonyms : ID-LV305 Plus ID G305; LV 305 Plus G 305; LV305 Plus G305;
NCIt definition : An immunotherapeutic combination product composed of LV305, an engineered lentiviral
vector that both targets dendritic cells (DCs) and contains nucleic acids encoding
the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer
vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant
(GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic
activities. Upon intradermal administration of LV305, the DC-targeting lentiviral
vector targets and binds to dermal DCs via the DC-specific intercellular adhesion
molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector,
the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the
immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing
cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection
of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed
on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated
DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction
of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against
NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody
response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor
cells, plays a key role in tumor cell proliferation and survival.;
Molecule name : CMB305; ID-CMB305; CMB 305;
Origin ID : C122922;
UMLS CUI : C4053576;
Semantic type(s)
- concept_is_in_subset
- has_target
